key: cord-0867834-plf2hm0y
authors: Colombani, Thibault; Eggermont, Loek J.; Rogers, Zachary J.; McKay, Lindsay G. A.; Avena, Laura E.; Johnson, Rebecca I.; Storm, Nadia; Griffiths, Anthony; Bencherif, Sidi A.
title: Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID‐19 Vaccines
date: 2021-05-17
journal: Adv Sci (Weinh)
DOI: 10.1002/advs.202100316
sha: 69529ba1ee7c48d9d51dc0ea4591809b17872d20
doc_id: 867834
cord_uid: plf2hm0y

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented global health crisis, resulting in a critical need for effective vaccines that generate protective antibodies. Protein subunit vaccines represent a promising approach but often lack the immunogenicity required for strong immune stimulation. To overcome this challenge, we first demonstrate that advanced biomaterials can be leveraged to boost the effectiveness of SARS‐CoV‐2 protein subunit vaccines. Additionally, we report that oxygen is a powerful immunological co‐adjuvant and has an ability to further potentiate vaccine potency. In preclinical studies, mice immunized with an oxygen‐generating COVID‐19 cryogel‐based vaccine (O(2)‐Cryogel(VAX)) exhibited a robust Th1 and Th2 immune response, leading to a sustained production of highly effective neutralizing antibodies against the virus. Even with a single immunization, O(2)‐Cryogel(VAX) achieved high antibody titers within 21 days, and both binding and neutralizing antibody levels were further increased after a second dose. Engineering a potent vaccine system that generates sufficient neutralizing antibodies after one dose is a preferred strategy amid vaccine shortage. Our data suggest that this platform is a promising technology to reinforce vaccine‐driven immunostimulation and is applicable to current and emerging infectious diseases. This article is protected by copyright. All rights reserved

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with over 30 million cases and nearly 1 million deaths as of September 2020 with no indications of slowing down. [1] In response, several strategies are currently under rapid investigation, including treatments (e.g., antivirals, antibodies, anti-inflammatory, and immunomodulatory factors), [2] [3] [4] and prophylactic vaccines (e.g., nucleic acid-based, protein subunit-based, recombinant viral vector-based, inactive or attenuated viral-based, virus-like particles). [5] [6] [7] Yet, only vaccines have the potential to confer global immunity. The stakes are high: The alternative is natural herd immunity, requiring several waves of infection over the next few years, a period characterized by high mortality, economic uncertainty, and a perturbed way of life. [8] Although two vaccine candidates have been approved by the Food and Drug Administration (FDA), [9, 10] it is unclear if they will alter the course of the pandemic and confer long term immunity. Therefore, there is a critical need to continue driving novel vaccination platforms into the clinic until SARS-CoV-2 is quelled, as well as to prepare for future pandemics.

Protein subunit vaccines have been approved to protect against infectious diseases with several currently commercially available, [11] yet they often lack the immunogenicity required to induce strong and long-lasting immunity. [5, 12] This is also exemplified by the recent delay of the Sanofi/GSK adjuvanted recombinant protein-based COVID-19 vaccine that demonstrated insufficient responses in older adults. [13] Biomaterial-based delivery systems can address this challenge [14] by enhancing vaccine immunogenicity while reducing toxicity through controlled presentation and release of antigens and immunomodulatory factors (e.g., cytokines and adjuvants). [15] Cryogels, polymeric biomaterials with a unique interconnected macroporous network, can be used as a platform for the controlled delivery of vaccine components, as well as to recruit, host, and program immune cells in situ. Previously, cryogels have been leveraged for cancer vaccines with promising results in preclinical melanoma and breast cancer models. [16, 17] Therefore, we hypothesized that a COVID-19 cryogel-based vaccine (Cryogel VAX ), consisting of immunomodulatory factors and viral antigens, would provide an effective platform to promote the activation of dendritic cells (DCs), master regulators of the immune response, and stimulate antibody-producing B cells in the draining lymph nodes (LNs). This strategy is expected to induce high titers of binding and neutralizing antibodies, resulting in an effective protection against SARS-CoV-2 infection.

Hypoxia, a hallmark of inflamed, infected, or damaged tissues, is due to an imbalance between oxygen supply and consumption. Additionally, this state is also inherent to biomaterials when injected or implanted into the subcutaneous space, likely due to poor vascularization and insufficient oxygen supply. [18] A low oxygen tension has shown to negatively impact DC function, including survival, differentiation, migration, activation, and antigen presentation. [19, 20, 21] Ultimately, this condition represents a major challenge when priming DCs, including with protein subunit vaccines. As a result, we proposed that local oxygen supply from the cryogel platform could reverse local hypoxia and potentiate the immune responses induced by SARS-CoV-2 protein subunit vaccines.

In this study, we fabricated SARS-CoV-2 vaccines by incorporating both the nucleocapsid protein (N) and the receptor-binding domain (RBD) of the spike protein (S) into hyaluronic acid-based cryogels. The RBD protein is responsible for virus entry into cells and induces the production of high affinity antibodies. [22] The N protein, known to be highly immunogenic, encapsulates the viral genomic RNA and contains specific T cell epitopes. [23, 24] Combining these two proteins may induce a strong multi-epitope immune response, activating both arms of the adaptive immune system (cell-based and humoral), and ultimately leading to the production of antibodies with high neutralizing activity. The cryogels also contained granulocyte macrophage colony-stimulating factor (GM-CSF), a molecule that stimulates various immune cells, including DCs, [25, 26] and the adjuvant CpG ODN 1826, a ligand for TLR9 (toll-like receptor 9) that activates DCs, specifically plasmacytoid DCs (pDCs). [27] [28] [29] These cryogel-based vaccines were formulated to induce a robust humoral immune response . [29, 30] . To enhance vaccine immunogenicity, oxygen was considered as an immunological co-adjuvant that would eliminate local hypoxia at the site of vaccine administration. [31] Thus, oxygen-producing calcium peroxide (CaO 2 ) particles and acrylate-PEG-catalase (APC) were incorporated within the cryogel-based vaccine formulations before freezing, as previously described. [32] The resulting oxygen-generating COVID-19 cryogel-based vaccine (O 2 -Cryogel VAX ) was designed to generate oxygen upon the reaction of CaO 2 with water and to eliminate hydrogen peroxide byproducts through a catalase-mediated breakdown. Herein, we first characterized the encapsulation and release of biomolecules from O 2 -Cryogel VAX and their potential to reverse hypoxia-associated DC inhibition. Next, we investigated the ability of the vaccines to promote immune cell infiltration locally, stimulate B cell production, and induce high antibody titers with strong neutralizing activity against the virus. Finally, we evaluated vaccine-induced antibody subclasses, T helper responses, cytokine secretion, and the resulting balance between Th1 and Th2 immune responses.

The capacity of O 2 -cryogels to reduce local hypoxia was first evaluated. O 2 -cryogels and cryogels were fabricated as previously described, [32] and their ability to generate oxygen in vitro was confirmed using contactless environmental oxygen probes ( Figure S1 ). As intended, O 2 -cryogels released oxygen in their surrounding environment for nearly 48 h, with oxygen level peaking at 310 μM after 3 h. On the contrary, catalase-free O 2 -cryogels produced an insignificant amount of oxygen, confirming the need to use this enzyme. Next, O 2 -cryogels and cryogels were subcutaneously injected in mice, and in vivo cellular hypoxia was tested with Hypoxyprobe™-1 after 24 h and 72 h ( Figure 1A ). As expected, 95 ± 3 % of infiltrated cells within (non-oxygen producing) cryogels were hypoxic as early as 24 h following injection. However, the fraction of hypoxic cells was significantly decreased for O 2 -cryogels to 68 ± 18% and 43 ± 12% after 24 h and 72 h, respectively. We also assessed the capacity of the biomaterials to prevent the inhibition of DCs when subjected to hypoxia.

In vitro, BMDCs were stimulated with CpG ODN 1826 in normoxic or hypoxic conditions for 24 h and exposed to either cryogels or O 2 -cryogels. As shown in Figure 1B , O 2 -cryogels restored DC activation with increased fraction of CD86 High CD317 High DCs, comparable to DCs stimulated under normoxic conditions. This suggests that local oxygen supply from cryogel-based vaccines could potentiate DC activation and enhance SARS-CoV-2 protein subunit vaccines. Therefore, O 2 -cryogels were used in this study as a biomaterial of choice to improve protein-based SARS-CoV-2 vaccines.

Next, hyaluronic acid-based cryogel vaccines were fabricated by cryogelation, as previously described ( Figure 1C , steps 1-3). [16, 26, 33] This process results in an elastic biomaterial with a highly interconnected macroporous network, allowing immune cells to traffic in and out of the cryogel. The encapsulation of RBD and N proteins within O 2 -Cryogel VAX polymer walls was characterized by confocal microscopy and release from the cryogel by ELISA ( Figure S2A -B). Both proteins were effectively entrapped within the polymer network. Both Cryogel VAX and O 2 -Cryogel VAX led to an initial burst release of the immunomodulatory factors (GM-CSF and CpG ODN 1826) and RBD antigen within the first 8 h and then about 35% of CpG ODN, 91% of GM-CSF, and 71% of RBD were delivered by 30 h (experimental endpoint) ( Figure S2B) . Notably, there were no differences among the encapsulation ( Figure S2C ) and release profiles of CpG ODN 1826, GM-CSF, and RBD for the two types of cryogels. Importantly, negligible amounts of Ca 2+ and H 2 O 2 are released from O 2 -cryogels ( Figure S2D -E), resulting in high BMDC viability ( Figure S2F ). These results suggested that cryogels and O 2 -cryogels are suitable platforms for controlled vaccine delivery.

We hypothesized that the protein antigens and adjuvants released from the vaccine would most likely be drained to the inguinal LNs and direct B cell activation. [34] [35] [36] Additionally, following immunization ( Figure 1C ), we anticipated that the cryogel-based vaccines would induce DC-mediated humoral immunity ( Figure 1D ). [26] This is supported with our previous findings on cryogel cancer vaccines where a sustained release of immunomodulatory factors (GM-CSF and CpG ODN 1826) promoted DC infiltration and stimulation. [26, 32, 33] Within the cryogels, DCs are expected to take up N and RBD protein antigens and be simultaneously stimulated by CpG ODN 1826 and additive oxygen. Cryogel VAX did, showing a 5-fold increase at day 56, and these titers were sustained for nearly 2 months (study endpoint). Similarly, O 2 -Cryogel VAX immunization resulted in high titers of N-specific binding IgG antibodies comparable to those induced by Freund VAX , and 3 and 5-times higher than those generated by Cryogel VAX and Bolus VAX, respectively. Figure 2D , upper). Importantly, 1.7% of O 2 -Cryogel VAX -induced anti-RBD IgG antibodies were neutralizing from day 21 onward ( Figure 2D , lower). We also assessed the neutralization potency of antibodies by plaque reduction neutralization test (PRNT) using

VeroE6 cells infected with authentic SARS-CoV-2 ( Figure 2E ). [34] As expected, O 2 -Cryogel VAX immunization led to high neutralizing titers, which intensified from day 21, reaching a reciprocal IC 50 value of nearly 10,000 at day 56 (study endpoint). Collectively, these data demonstrated that the cryogel platform potentiates vaccine efficacy. Furthermore, additive oxygen as a co-adjuvant strongly boosted the humoral response, as shown by the production of antibodies with high neutralizing activity and presumably increased binding affinity to RBD. Values, indicative of individual LNs or cryogels, are presented as mean ± SEM (n=10). Data were analyzed using two-way ANOVA and Bonferroni post-tests to evaluate differences between conditions at the same time point (colored stars indicate statistical significance within a given condition of the same color), *p < 0.05, **p < 0.01 and ***p < 0.001.

Next, to evaluate the immunostimulatory effects of cryogel-based SARS-CoV-2 vaccines, we analyzed the balance between Th1 and Th2 immune responses. Production of antibody subclass IgG1 is indicative of Th2 responses, and IgG2a/b/c and IgG3 are indicative of Th1 responses. [35] In our study, vaccines across all groups elicited IgG2 and IgG1 subclass RBD-binding antibodies, indicating induction of both Th1 and Th2 immune responses ( Figure 4A ). Both cryogel-based vaccines promoted the production of IgG2b. However, O 2 -Cryogel VAX improved IgG1 production resulting in lower IgG2a/IgG1 and IgG2b/IgG1 ratios ( Figure 4B ). Interestingly, O 2 -Cryogel VAX was the only vaccine that induced IgG3 production ( Figure 4A-B) . Importantly, relatively low IgE titers were detected for Bolus VAX , 

Nearly every decade for the past 30 years, a novel coronavirus pandemic emerges, pushing the healthcare system to its limit. [36] Although the current outbreak had long been predicted, SARS-CoV-2 has created the most severe crisis in recent history. [37, 38] The rapid development of an effective and safe vaccine against this virus is the most effective strategy to end this pandemic. Among them, protein subunit vaccines have been widely investigated against SARS-CoV-2 due to their performance and safety record, and such vaccines have already shown promising early results in phase 1/2 clinical trials. [14] Yet, subunit vaccines still have to overcome their lack of immunogenicity immunogenicity. [39] In addition, an ideal antiviral vaccine should be versatile and rapid to design, enabling rapid response to the public health emergency. To overcome these challenges, our team leveraged a cryogel-based vaccine platform to strengthen protein subunit vaccines and induce a strong and sustained immunity against SARS-CoV-2. [26] In addition, we showed that oxygen is a powerful immunological co-adjuvant that shapes and reinforces the immune response. This work demonstrated how robust and modular the cryogel-based vaccine technology is, which was successfully and quickly adapted from cancer to an infectious disease at breakneck speed (< 3 months).

We found that Cryogel VAX triggers both Th1 and Th2 immune responses while enhancing the efficacy of a conventional protein subunit vaccine by 100-fold (Bolus VAX ).

This is most likely due to the ability of cryogels to control the release of immunomodulatory [26] Furthermore, this supports our hypothesis that Cryogel VAX may act as a distant immune cell training platform that would reinforce our prime-boost vaccination strategy.

Although promising, Cryogel VAX has been associated with a number of limitations in this study, including a decrease in anti-SARS-CoV-2 IgG antibodies after 42 days and low concentrations of Th1 cytokines. In light of these findings, we explored the use of oxygen as an immunological co-adjuvant to potentiate vaccine efficacy. We confirmed that O 2 -cryogels did not produce any harmful byproducts and were cytocompatible while generating a controlled level of oxygen. We demonstrated that supplemental oxygen not only promoted CD4+ and CD8+ T cell responses against SARS-CoV-2, but also promoted the production of Th1-biased and pro-inflammatory cytokines. Additionally, O 2 -Cryogel VAX remarkably boosted humoral immunity with long-lasting production of binding antibodies (5-fold higher at day 56) and high IgG1 neutralizing activity with a single injection. This suggests the induction of a balanced Th1 and Th2-associated immune responses. Strikingly, IgG1 skewing was observed with O 2 -Cryogel VAX . This may be attributed to oxygen transport from the vaccine site to the germinal centers, presumably leading to IgG1 class switching and proliferation of activated B cells when exposed to increased oxygen tension. [43] Interestingly, More research is needed to assess the duration of our vaccine-induced immune responses, especially in non-human primates and humans, as well as to more carefully dissect the immune mechanism by which both the humoral and cellular immune responses are triggered. [40, 41] Furthermore, examining immune cell populations at earlier time points, the synergistic interaction of N and RBD proteins during immune priming, and the contribution of each of the immunomodulatory factors may further shed light on the vaccine mode of action. Although we previously reported that CpG ODN and GM-CSF can be released up to 40 days from cryogels, [26] the release kinetics of the antigens and adjuvant from O 2cryogel VAX need to be further investigated and over an extended period of time. Moreover, a deeper understanding of the spatiotemporal diffusion of oxygen could be leveraged to further boost vaccine efficacy. While cryogel-based vaccines have proven to induce long-lasting immunity against melanoma, [26] additional studies are required to confirm long-lived protective immunity and the induction of central and effector T cell memory in the context of COVID-19. In addition, the effectiveness of O 2 -Cryogel VAX in aged or obese animals needs to be tested. Finally, a toxicology analysis in combination with a careful evaluation of biomaterial degradation are necessary to assess long-standing vaccine safety .

In summary, our study unveils the magnitude of an advanced biomaterial-based technology to harness the power of protein subunit vaccines, leading to a rapid and protective anti-SARS-CoV-2 immune response. Additionally, we report the synergistic effect of vaccines engineered to provide oxygen as a powerful immunological co-adjuvant. Lastly, although our efforts focused on protein subunits, this platform is compatible with other strategies, such as live attenuated or inactivated pathogens and nucleic acid vaccines, and may boost the efficiency of existing vaccines or those under development. Although several vaccines have proven to be effective in phase 3 clinical trials, their stability as well as the number of required doses and the duration of their protection might not be optimal. [42] Our study opens new possibilities to leverage vaccines, such as the one described here for COVID-19, and help quickly develop new versions as the virus could mutate and be more infectious. For instance, the recent new viral mutations of SARS-CoV-2 leading to a virus variant in Europe that is thought to spread more easily. This is a good example of the mutability of SARS-CoV-2 and its danger leading to more death, economic uncertainty, and travel restrictions. [43, 44] Lastly, this platform is potentially applicable in reinforcing vaccines for other infectious diseases and any conditions that may require stimulating the immune system.

Cryogels were fabricated as previously described by redox-induced free radical cryopolymerization of hyaluronic acid glycidyl methacrylate (HAGM, 4% w/v) at subzero temperature (-20°C). [16, 26, 32] Briefly, the polymer solution was precooled at 4°C prior to adding tetramethylethylenediamine (TEMED, 0.42% w/v, Sigma-Aldrich) and ammonium persulfate (APS, 0.84% w/v, Sigma Aldrich). Then, the mixture was transferred into Teflon® molds (4x4x1 mm 3 , cubiform with 2 square-shaped sides, 16 μL), placed in a freezer at -20°C, and allowed to cryopolymerize for 16 h. Finally, the newly formed cryogels were thawed at room temperature (RT) to remove ice crystals and washed with Dulbecco's Phosphate Buffered Saline (PBS, Gibco). For O 2 -cryogel fabrication, acrylate-PEG-catalase (APC, 1% w/v, Sigma-Aldrich) and CaO 2 (1% w/v) were mixed with the cryogel polymer solution before the addition of TEMED and APS as previously reported. [32] 

Protein subunit-based vaccines were fabricated by formulating (1) 

Animal experiments were carried out in compliance with the National Institutes of Health (prime) and day 56 (prime + boost) and then dissociated as previously described. [26, 32] Hypoxia studies were performed on 6-8-week-old female C57BL/6 mice (Charles River).

Cryogels and O 2 -cryogels were suspended in 100 µL PBS and injected SC into mouse flanks. 

Dendritic cells (DC) activation studies were performed using bone marrow-derived dendritic cells (BMDCs) generated from 6-8-week-old female C57BL/6 mice (Charles River) as previously described. [26] Briefly, femurs of mice were explanted, disinfected in 70% ethanol BMDCs were collected at day 10 (non-adherent cells) and used to evaluate DC activation in normoxia or hypoxia.

BMDCs were incubated in complete RPMI medium containing 10 ng/mL mGM-CSF at 37°C

in either humidified 5% CO 2 / 95% air (normoxia) or 5% CO 2 / 1% O 2 / 94% N 2 (hypoxia)

incubator (Napco CO 2 1000 hypoxic incubator, Thermo Fisher Scientific) for 24 h. Cryogels, Concentration of purified proteins was determined by UV-Vis absorbance measurements at 280 nm, after correcting for fluorophore absorbance, using the Nanodrop One (Thermo Fisher Scientific). O 2 -Cryogels containing the fluorescently labeled RBD and N proteins were fabricated as described above. After thawing, cryogels were washed four times with 1 mL of PBS and imaged by confocal microscopy (Zeiss 800).

To determine the in vitro release kinetics of GM-CSF, CpG-ODN, and RBD protein from 

Anti-RBD IgG and IgM antibody titers were determined using a SARS-CoV-2 Spike S1- 

The detection of neutralizing antibodies against SARS-CoV-2 that block the interaction between RBD and the human ACE2 (hACE2) cell surface receptor was determined using an sVNT according to the manufacturer's protocol (Genscript). Briefly, heat-inactivated mouse sera were pre-incubated with HRP-RBD (30 min at 37°C) to allow the specific binding of neutralizing antibodies. Then, the mixture was transferred into a plate coated with hACE2 and incubated for 15 min at 37°C. The unbound HRP-RBD, as well as HRP-RBD bound to non-neutralizing antibody, will interact with the hACE2, while neutralizing antibody-HRP-RBD complexes will remain in suspension and will be removed during washing. TMB substrate was used to detect the non-neutralized HRP-RBD. Therefore, the absorbance was inversely proportional to the titer of anti-SARS-CoV-2 neutralizing antibodies. For this experiment, 10-fold dilutions of mouse sera (10 -1 to 10 -8 ) were used.

Cytokine levels in mouse sera and cryogels were quantified using LEGENDplex™ mouse Th The monolayers were fixed with 10% neutral buffered formalin for at least 6 h (NBF, Sigma-Aldrich) and stained with 0.2% aqueous Gentian Violet (RICCA Chemicals) in 10% NBF for 30 min, followed by rinsing and plaque counting. The half maximal inhibitory concentrations (IC 50 ) were calculated using GraphPad Prism 8 as previously described. [34] Immune cell characterization in cryogels and LNs Flow cytometry measurements were done using the Attune NxT flow cytometer (Thermo Fisher Scientific).

Splenocytes were incubated with 1) 20 ng/mL PMA (Sigma Aldrich) and 1 ug/mL ionomycin 

Flow cytometry data were processed using FlowJo software and manual gating was performed as depicted in Figures S4A and S5A . Statistical analysis was conducted using GraphPad Prism 5 software. Data were analyzed using one-way ANOVA and Bonferroni post-tests to evaluate differences between time points (underlined dark stars indicate statistical significance) or two-way ANOVA and Bonferroni post-tests to evaluate the difference between different conditions/treatments (colored stars indicate statistical significance within a given condition of the same color). Values represent the mean ± standard error of the mean (SEM) and p-values below 0.05 were considered statistically significant.

An immunostimulatory oxygen-generating cryogel platform has been developed to boost COVID-19 vaccines. Cryogels loaded with SARS-CoV-2 Nucleocapsid (N) and receptorbinding domain (RBD) proteins (antigens), CpG (adjuvant), and GM-CSF (immunomodulatory factor) activated both arms of the adaptive immune system.

Additionally, oxygen, used as a co-adjuvant, remarkably boosted the production of binding and neutralizing antibodies against the virus. This advanced biomaterial offers a new avenue to reinforce vaccines against infectious diseases and beyond.

Pfizer-BioNTech COVID-19 Vaccine | FDA

Moderna COVID-19 Vaccine | FDA

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly | GSK

Authors thank Nancy R. Gough (BioSerendipity) for critical evaluation and editing The authors declare no conflict of interest.

Supporting Information is available from the Wiley Online Library or from the author.